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Introduction  
Aged and geriatric horses are becoming increasingly important in equine practice with referral 
hospitals documenting 5-10 fold increases in the proportions of geriatric patients over several  
decades. 1,2 This is due, in part, to better veterinary diagnosis and treatment options, but also is due to 
their owners presenting them for that care.  Owners of aged horses are concerned about the health, 
welfare and quality of life of their aged animals, which is often due to a deep human-horse bond that 
has developed over many years of ownership. 3 Geriatric horses are owned for longer than younger 
horses 4 and surveys of management practices in epidemiological studies reflect a high level of 
owner dedication to these animals. 5,6 Pituitary pars intermedia dysfunction (PPID) is one of the more 
common geriatric diseases in horses, affecting over 20% of horses age 15 years and over, with an 
increasing prevalence with each subsequent year of age. 7 Although affecting older horses, 
veterinarians should be aware of the importance of their aged animals to many horse owners when 
planning management options for them. This in-depth review will discuss treatment and management 
of PPID, one of the most important diseases of aged horses, with a special focus on those cases with 
laminitis.  
  
Initial Advice  
Following a diagnosis of PPID, it is vital to fully inform the horse owner about the treatment options.  
Unlike the case a decade ago where conservative management was sometimes still advocated, 
medical treatment of PPID is now the accepted ‘norm’ and owners should have this option offered to 
them. As well as the availability of licensed medication, there is robust evidence supporting 
significant clinical and endocrinological improvements in more than three quarters of PPID horses 
that undergo treatment 8 and long-term improvements over many years have been maintained. 9  
During the initial explanation of the disease, it is important to ensure horse owners are aware of the 
disease and understand its basic pathophysiology and how the treatment works. A comparison with 
Parkinson’s disease in humans or ‘accelerated aging’ may be the best way to explain it to owners, 
helping owners to understand why a medical therapy might be appropriate. McFarlane 10 suggests 
that the dopaminergic neurodegenerative process leading to PPID is associated with aging and has 
shown many similarities with Parkinson’s disease in humans. The neurodegeneration causes a loss of 
dopaminergic inhibition of the pars intermedia of the pituitary gland 11. The result is a loss of 
negative control of pars intermedia endocrine function and the overproduction of 
proopiomelanocortin (POMC) derived peptides produced by the pars intermedia melonotrope cells 
including adrenocorticotropin (ACTH), alpha melanocyte stimulating hormone (α-MSH), beta 
endorphin (β-endorphin) and corticotrophin-like intermediate peptide (CLIP). This overactive pars 
intermedia becomes hyperplastic on histological examination initially and in more advanced disease 
can become adenomatous, 12 but is not a primary tumor like owners may assume.  
Treatment  
Medical treatment of PPID involves daily oral administration of pergolide, a dopamine agonist, 
which is licensed (FDA approved) for use at a dose from 0.002 – 0.01 mg/kg PO q24h.a  Treatment 
should be initiated at the low end of the dose range (to the nearest  
0.5 mg) and gradually increased, if required, based on clinical and endocrinological response. 13    
Body Weight  Starting Daily Dose  
200-350 kg  0.5 mg  
350-600 kg  1.0 mg  
601-850 kg  1.5 mg  
  
Side effects  
Although pergolide has few specific side effects, up to a third of treated horses will demonstrate 
transient inappetance on pergolide, and around 10% may appear dull or lethargic. 8 These side 
effects, especially inappetance, were more common when pergolide was first used at much higher 
initial doses. 14 Therefore, careful attention to gradual increases of the dose can reduce the 
occurrence of these side effects. If signs of inappetance or depression are observed, the dose can be 
reduced by increments of 0.001 mg/kg BW 13 or stopped for a short period (2-3 days or till appetite  
returns) and the dose restarted at half of the original dose. 15,16   
Interestingly, pergolide administered in target animal safety studies, depression and/or anorexia were 
not observed in normal horses, even at doses as high as 0.008 mg/kg for 6 months. 8 There were 
decreases in heart rate variably between geldings and mares, but only to the normal range. 8 Further 
research using normal horses in a blinded controlled cross over design trial using more detailed heart 
rate observations using holter monitor recording at rest, during stimulation and exercise did not 
demonstrate a difference in heart rate between groups. 17  
Despite the frequency of side effects, it is important to recognize that signs of inappetance of lethargy 
are non-specific and may accompany many diseases. Aged horses, even without PPID, have an 
increased risk of concurrent disease, 4 so on identification of these clinical signs, especially if they 
don’t rapidly resolve with a reduction of dose, it may also be pertinent to investigate for concurrent 
disease.  
Monitoring  
Notwithstanding the improvements that most horses can expect from medical treatment, owners need 
to be aware that treatment is not curative, and medical treatment is a commitment that should be 
continued indefinitely, with monitoring, dose adjustments and ongoing care important parts of 
therapy. 13   
General health monitoring  
Most horses with PPID will be in their ‘teens’ or older, with an increasing likelihood of diagnosis 
every year after 15 years of age.7 Aged and geriatric horses have an increased susceptibility to a 
range of conditions and diseases, particularly dental disease (including periodontal disease), 
lameness, eye conditions, heart or lung conditions and skin conditions (including tumors such as 
sarcoids and melanomas). 4 PPID may increase the risk of intestinal parasitism 18 but does not alter a 
routine hematological or biochemical profile. 7 Despite an association between alterations in blood 
tests and PPID being reported, 16 it is important to note these have only been found in case series and 
not field based epidemiological research. 19 Case series rely on horses presented for veterinary care, 
and hence suffer from owner bias. As noted in the companion paper on this in depth session, 
epidemiological research has shown that many of the clinical signs of PPID are considered normal 
signs of aging by horse owners, including hypertrichosis and muscle atrophy, 20 so owners may 
inadvertently delay presentation for veterinary care until concurrent disease occurs. 19 Therefore, 
alterations in blood tests and concurrent illnesses should be investigated as concurrent disease, not 
ignored or presumed only associated with PPID.  
In the aged population of horses presenting with PPID, there is a higher possibility of serious dental 
problems as well as periodontitis and diastema than younger horses 21 so dental work should be 
carried out with due veterinary care including sedation, pain relief and anti-inflammatory or other 
medication as necessary. If owners are fully informed of the high prevalence of these conditions in 
their horses’ age bracket and engage in regular health checks with appropriate blood testing, then the 
best outcomes can be achieved.  
Monitoring clinical signs of PPID  
Improvements in clinical signs are important monitoring tools and attention should be paid to trying 
to collect these as objectively as possible rather than just relying on endocrine ‘numbers’. Body 
condition score (and muscle score), hair coat, demeanor, appetite, Obel grade of lameness if lame (or 
evidence of subclinical laminitis like laminitic rings, widened white line or dropped soles if not) and 
water intake can all be monitored. Baseline values should be obtained in consultation with the owner, 
then subsequently horse owners can be encouraged to monitor and record these e.g. monthly.   
PPID endocrine monitoring   
Endocrine monitoring should include both monitoring of PPID as well as monitoring for the risk of 
laminitis Testing for endocrine disease in the middle aged and older horse is covered in detail in a 
companion paper in this in depth session, but monitoring is achieved by repeating the endocrine 
testing used for diagnosis. For example, if basal ACTH was used for diagnosis, this value can be 
used as the baseline ACTH for follow up evaluation of response to treatment. The first follow up for 
a horse starting treatment for PPID should be within 4-6 weeks. 13,16 At this time ACTH values 
should have decreased substantially (e.g. by at least 50%) or be within the normal reference range, 
bearing in mind the seasonal increase in ACTH from late summer. 22,23 Although clinical signs may 
take longer to respond, most owners will detect an improved, brighter demeanor of their horse within 
this first time frame. 16 If clinical or endocrine improvements are not noted, increase the dose of 
pergolide by 0.001 – 0.002 mg/kg BW/day, to a maximum of 0.01 mg/kg. Each increment in dose 
should be monitored with follow-up assessments of clinical signs and endocrinological testing 
similarly (within 1-2 months) until the horse stabilizes. If clinical signs have stabilized for more than 
3 months on a dose greater than 0.002mg/kg/day pergolide, a decrease of the pergolide dose by 0.001 
mg/kg BW/day can be attempted, with the aim to reduce the dose back down to 0.002 mg/kg 
BW/day, bearing in mind that lower doses can result in treatment failure 13  
Once a suitable dose has been determined, follow up monitoring can decrease to 1 or 2 times a year. 
Where twice yearly monitoring is able to be performed, one of these follow up tests should be timed 
to occur during September when there is peak ACTH and maximal sensitivity for diagnostic testing, 
23 bearing in mind the natural stimulation may push even a well-controlled horse a little outside of 
the seasonal reference range.  
Monitoring for the risk of laminitis  
In addition to monitoring PPID, it is also worthwhile measuring insulin dysregulation, either basally 
or dynamically, and this is imperative in horses with a prior history or current laminitis, including the 
presence of laminitic hoof changes. In horses with PPID, hyperinsulinemia is highly associated with 
laminitic lesions 25 and laminitis 7. The presence of hyperinsulinemia is an important prognostic 
indicator for PPID survival overall 24 and the degree of insulin dysregulation provides a good 
indication of the risk of laminitis. Basal or dynamic (response to oral glucose or corn syrup) tests for  
hyperinsulinemia are recommended. 13,16 The timeframe for monitoring hyperinsulinemia can usually 
fit in with ACTH monitoring, but in some cases with poorly controlled laminitis, yet well controlled 
ACTH, it may need to be more frequent.  
Management of the insulin dysregulated PPID horse (at risk for laminitis)  
Insulin dysregulated horses should be managed to reduce hyperinsulinemia, but care should be taken 
not to treat exactly the same as horses with equine metabolic syndrome (EMS) without PPID. 
Prognosis is better in horses with controlled insulin dysregulation, even if this is unable to be 
completely normalized. 24 However, some advanced cases of PPID with insulin dysregulation can 
prove difficult to manage, even in the face of normalization of ACTH concentrations. In these cases, 
management of the insulin dysregulation using careful dietary control is advised.   
Dietary considerations  
Tailored dietary restriction and exercise has been shown to improve insulin dysregulation in horses 
with EMS 26 but can be less effective in horses with both PPID and insulin dysregulation. 27 In one 
study horses with both PPID and insulin dysregulation had a greater degree of insulin dysregulation 
and poorer response to dietary management than horses with insulin dysregulation only. 27 Horses 
with PPID are already at risk for muscle atrophy, most likely as a result of muscle catabolism 28 so 
dietary consideration should focus on the insulinemic response to feeds rather than on management 
of obesity and weight loss. In the author’s opinion, even in obese PPID affected horses, weight loss 
should be carefully monitored and reductions of 0.25 – 0.5% BWT per week should be the 
maximum. Where persistent hyperinsulinemia exists, basally or dynamically, it is important to focus 
on the carbohydrate content of the diet, especially the non-structural carbohydrate content of the 
forage component which often forms the bulk of the diet.  
Soaking hay is a good way to reduce water soluble carbohydrate content of hay and produces 
dramatic reductions in the insulinemic responses to forage in both normal and insulin dysregulated 
ponies (without PPID), 29 but soaking also results in leaching of water soluble minerals (especially 
sodium, chloride, potassium, calcium, phosphorus, magnesium and sulfur), 30 so careful attention to 
appropriate balancing of the diet is recommended.  Similarly, although protein is not lost by soaking 
hay, 30 where horses are on a forage only diet where protein content can be marginal, careful 
attention to protein (especially high quality amino acid supplementation) and vitamin and mineral 
supplementation is important to prevent and reverse muscle loss and atrophy. 28  
In horses with more marked weight loss or unable to cope with long fiber, for example, due to dental 
disease, low glycemic short fiber or complete rations can be purchased. Higher fat rations provide a 
high density caloric source and tend to induce lower insulinemic responses when fed.  
Further treatment   
In some cases, pharmaceutical management such as metformin may help, although evidence 
supporting their effect on reducing hyperinsulinemia is limited 13 Exercise, where permitted due to 
concurrent orthopedic disease or laminitis is also useful to improver insulin dysregulation in horses 
with PPID.   
Conclusions  
PPID is an important disease of aged and geriatric horses. Although affecting older horses, 
veterinarians should be aware of the importance of aged animals to many horse owners when 
planning management options for them. There is now good evidence to suggest at least 75% of 
treated horses should respond to therapy, including advanced cases. Less advanced cases (and some 
advanced ones) can return to athletic function and even competition level activity, although 
competing on pergolide is still not allowed in many events so this should be checked before 
competition. Notwithstanding the improvements that most horses can expect from medical treatment, 
owners need to be aware that treatment is not curative, and medical treatment is a commitment that 
should be continued indefinitely. Monitoring and ongoing care are important parts of therapy. 
Monitoring clinical signs of PPID will help inform dose adjustments and monitoring for and treating 
concurrent disease will lead to optimal outcomes. Endocrinological monitoring for PPID is important 
to direct appropriate dose adjustments and endocrinological monitoring for insulin dysregulation will 
inform about the risk of laminitis and overall prognosis.  
 a Prascend, Boehringer Ingelheim 
References  
1. Brosnahan MM, Paradis MR. Demographic and clinical characteristics of geriatric horses:  
467 cases (1989-1999). J Am Vet Med Assoc. 2003; 223: 93-98.  
2. Traub-Dargatz JL, Long RE, Bertone JJ. What is an “old horse” and its recent impact? In: 
Bertone J, editor. Equine Geriatric Medicine and Surgery. St Louis: WB Saunders; 2006. pp  
1-4.   
3. McGowan C. Welfare of Aged Horses. Animals. 2011; 1(4):366-76.  
4. Ireland JL. Demographics, management, preventive health care and disease in aged horses.  
Vet Clin North Am Equine Pract. 2016; 32(2):195-214.  
5. McGowan, T. W.; Pinchbeck, G.; Phillips, C.; Perkins, N.; Hodgson, D. R.; McGowan, C. M. 
A survey of aged horses in Queensland, Australia. Part 1: Management and preventive health 
care. Aust. Vet. J. 2010; 88, 420-427.  
6. Ireland, J.L.; Clegg, P.D.; McGowan, C.M.; McKane, S.; Pinchbeck, G.L. A Cross-sectional 
Study of Geriatric Horses in the United Kingdom Part 1: Demographics and Management 
Practices Equine vet. J. 2011; 43, 30-6.  
7. McGowan TW, Pinchbeck GP, McGowan CM. Prevalence, risk factors and clinical signs 
predictive for equine pituitary pars intermedia dysfunction in aged horses. Equine vet. J.  
2013; 45(1):74-9.  
8. NADA Freedom of Information Summary – Prascend tablets for the control of clinical signs 
associated with pituitary pars intermedia dysfunction (equine Cushing’s disease) in horses.  
2011; Available from: 
http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/F 
OIADrugSummaries/UCM280354.pdf.  
9. Schott, H.C. 2nd Pituitary pars intermedia dysfunction: challenges of diagnosis and 
treatment. In: Proceedings of the Annual Convention of the AAEP 2006; pp60-73.  
10. McFarlane D. () Advantages and limitations of the equine disease, pituitary pars intermedia 
dysfunction as a model of spontaneous dopaminergic neurodegenerative disease. Ageing Res 
Rev. 2007; 6(1):54-63.  
11. McFarlane D. Equine pituitary pars intermedia dysfunction. Vet Clin North Am Equine Pract.  
2011; 27(1):93-113.  
12. Miller MA, Pardo ID, Jackson LP, Moore GE, Sojka JE. Correlation of pituitary 
histomorphometry with adrenocorticotrophic hormone response to domperidone 
administration in the diagnosis of equine pituitary pars intermedia dysfunction. Vet Pathol.  
2008; 45(1):26-38.  
13. Durham AE, McGowan CM, Fey K, Tamzali Y, Kolk, JH. Pituitary pars intermedia 
dysfunction: diagnosis and treatment. Equine vet educ. 2014; 26, 216-223.  
14. Beech J. Treatment of hypophysial adenomas. Compend Contin Educ Pract Vet. 1994;  
16:921–923.  
15. National Office of Animal Health (NOAH) Compendium. Prascend 1 mg tablets for horses 
datasheet. 2017; Available from: http://www.noahcompendium.co.uk/?id=-447750   
16. Equine Endocrinology Group Recommendations for the Diagnosis and Treatment of Pituitary 
Pars Intermedia Dysfunction (PPID) Revised June 2017; Available from 
https://sites.tufts.edu/equineendogroup/files/2017/11/2017-EEG-Recommendations-PPID.pdf   
17. McGowan CM, Dugdale AH, Ireland JL, and Argo CMcG. Effect of pergolide on heart rate 
and behavioural responses to a novel object. European Equine Endocrinology Symposium, 
2014; Windsor UK pp. 44-45.  
18. McFarlane D, Hale GM, Johnson EM, Maxwell LK. Fecal egg counts after anthelmintic 
administration to aged horses and horses with pituitary pars intermedia dysfunction. J Am Vet  
Med Assoc. 2010; 236(3):330-4.  
19. Ireland, JL and McGowan CM. Epidemiology of pituitary pars intermedia dysfunction: A  
systematic literature review of clinical presentation, disease prevalence and risk factors. Vet 
J. 2018; 235:22-33..  
20. Ireland JL, Clegg PD, McGowan CM, McKane SA, Pinchbeck GL. Cross-sectional study of 
geriatric horses in the United Kingdom Part 2: Health care and disease. Equine vet J. 2011; 
43, 37-44.  
21. Wilson GJ, Liyou OJ. Examination of dental charts of horses presented for routine dentistry 
over a 12 month period. Austr. Equine vet. 2005; 24:79–83.  
22. Copas VE, Durham AE. Circannual variation in plasma adrenocorticotropic hormone 
concentrations in the UK in normal horses and ponies, and those with pituitary pars 
intermedia dysfunction. Equine vet J. 2012; 44, 440-3.  
23. McGowan TW, Pinchbeck GP, McGowan CM. Evaluation of basal plasma a-
melanocytestimulating hormone and adrenocorticotrophic hormone concentrations for the 
diagnosis of pituitary pars intermedia dysfunction from a population of aged horses. Equine 
vet J. 2013; 45, 66-73.  
24. McGowan CM, Frost R, Pfeiffer DU and Neiger R. Serum insulin concentrations in horses 
with equine Cushing's syndrome: response to a cortisol inhibitor and prognostic value.  
Equine vet J. 2004; 36: 295-298.  
25. Karikoski NP, Patterson‐Kane JC, Singer ER, McFarlane D, McGowan CM. Lamellar 
pathology in horses with pituitary pars intermedia dysfunction. Equine vet J. 2016;  
48(4):472-8.  
26. Morgan RA, Keen JA, McGowan CM. Treatment of equine metabolic syndrome: A clinical 
case series. Equine Vet J. 2016; 48(4):422-6.  
27. McGowan CM, Unpublished data.  
28. Aleman M, Watson JL, Williams DC, LeCouteur RA, Nieto JE, Shelton GD. Myopathy in 
horses with pituitary pars intermedia dysfunction (Cushing’s disease). Neuromuscul Disord.   
2006; 16(11):737-44.  
29. Carslake HB, Argo CM, Pinchbeck GL, Dugdale AH, McGowan CM. Insulinaemic and 
glycaemic responses to three forages in ponies. Vet J. 2018; 235:83-9. 
30. Mack SJ, Dugdale AH, Argo CM, Morgan RA, McGowan CM. Impact of water-soaking on 
the nutrient composition of UK hays. Vet Rec. 2014; 174(18):452.  
  
COI Statement  
Dr. Catherine McGowan’s institution, the University of Liverpool, has received funding from 
Boehringer Ingelheim related to this paper in the form of a research grant entitled “Behavioural and 
heart rate responses to pergolide in normal horses” 2013-2104, plus the University has received 
consultancy funding for Dr McGowan’s work as a Key Opinion Leader for talks and webinars related 
to PPID as part of Boehringer Ingelheim’s support for the licensed form of pergolide, Prascend.   
  
